Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Stock Jumped Today

By Keith Speights – May 20, 2020 at 3:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Momentum is continuing from the biotech's positive pipeline update last week.

What happened

Shares of ImmunoGen (IMGN 5.60%) were jumping 13.2% higher as of 3:11 p.m. EDT on Wednesday. The company didn't report any news. Instead, ImmunoGen's gains appeared to reflect continued interest from investors following the biotech's announcement last week of positive initial data from the Forward II phase 1/2b study evaluating mirvetuximab soravtansine in combination with Avastin as a treatment for ovarian cancer.

So what

ImmunoGen stock is up close to 30% since its May 13 update for the Forward II study. The initial results showed that the combination of mirvetuximab and Avastin demonstrated promising anti-tumor activity as well as a favorable safety profile. 

Scientist looking through a microscope

Image source: Getty Images.

The most notable result was a confirmed overall response rate of 61% in patients with high folate receptor alpha expression. Several types of cancer, including ovarian cancer, are often linked with expression of the protein.

But why are investors so excited about initial results from a phase 1/2b study? Probably because the encouraging data increases the level of confidence about the prospects for positive results for the late-stage Soraya study evaluating mirvetuximab as a monotherapy in treating platinum-resistant ovarian cancer. 

Now what

ImmunoGen continues to enroll patients in the Soraya study. Results from this study, which aren't expected until the middle of next year, could be a major catalyst for the biotech stock. In the meantime, the company plans to present updated data from the Forward II study in the fall of 2020 and should file for FDA approval to begin a phase 1 study of IMGC936 by the end of June. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen Stock Quote
$5.66 (5.60%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.